Manufacturing Chemist Interview: Alistair Hay Head of Peptide Business and Process Development
From dark art to an age of enlightenment
Dr Kevin Robinson sits down with Almac Sciences’ Alistair Hay to discuss the recent happenings in Almac’s GMP peptides business, in terms of growth, development and strategic operations. They also discuss the company’s current focus on neoantigen-derived vaccines that harness the body’s own immune system to fight cancer.
Read the full article below
